Dr. Ronald B. Natale, MD

Dr. Natale practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Natale's NPI, 1285734350, was assigned on September 25, 2006. Dr. Natale graduated from Wayne State University School Of Medicine in 1974. Dr. Natale holds California license C43090.

Dr. Natale's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Natale's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Natale practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Natale's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Natale is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Natale's licenses on file in 3 states: California, Michigan and New York.

Dmand AI lists lung cancer among the conditions Dr. Natale treats.

CMS data shows 349 Medicare services from Dr. Natale across 3 procedure codes in 2024, all of them office visits, for 116 Medicare patients. Medicare paid $34,553 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 116 Medicare patients who saw Dr. Natale in 2024. The largest group is 75 to 84, with 50 patients. 75% of them have cancer, and 75% have high blood pressure. 23% are also on Medicaid. Their average risk score is 3.47, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Natale's median patient age at 75, with 64% women.

In 2024, Dr. Natale wrote 119 Medicare Part D claims for 30 patients. 49% of them were for generic drugs. CMS names the drug for 65 of them, across 5 drugs with 11 or more claims each, at $726,227 in total drug cost. In 2023, CMS named 38 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Natale for performance year 2024, reported as part of a group.

Dmand AI links 123 papers to Dr. Natale, published from 2004 to 2020. 2017 was the busiest year, with 7. The most frequent topics are Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Carcinoma, Non-Small-Cell Lung. Dr. Natale has published most often in J Clin Oncol. Dr. Natale's most frequent co-authors are Mark A. Socinski, MD, Elward David Crawford, MD and Heather Ann Wakelee, MD.

Dmand AI links Dr. Natale to 12 clinical trials, 5 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Adenocarcinoma of Lung. Eli Lilly and Company sponsors the most, 2.

CMS Open Payments shows 140 general payments to Dr. Natale from 5 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 80% of the total. AstraZeneca Pharmaceuticals LP paid the most, $152,186.

Dmand AI lists 6 awards for Dr. Natale, most recently America's Top Doctors in 2014.

Dr. Natale graduated from Wayne State University School Of Medicine in 1974.

Dr. Natale is in network with 5 carriers, including Blue Cross Blue Shield of Massachusetts, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.